Minovia Therapeutics Wins FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome

Minovia Therapeutics Ltd., a clinical-stage biotech company focused on mitochondrial disease therapies, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead investigational drug, MNV-201, for the treatment of Myelodysplastic Syndrome (MDS), a serious age-related blood disorder. This designation adds to existing FDA Fast Track and Rare Pediatric Disease recognitions for MNV-201 in MDS and Pearson Syndrome, respectively.

The Orphan Drug status highlights the FDA’s acknowledgment of the urgent need for treatments targeting rare diseases affecting fewer than 200,000 people in the U.S. It also provides Minovia with benefits such as tax credits and market exclusivity to support the drug’s development.

“MNV-201 targets mitochondria, a critical organelle, and this FDA recognition underscores its potential impact on smaller patient populations with unmet needs,” said Minovia CEO Natalie Yivgi-Ohana, Ph.D. Minovia’s Chief Scientific Officer Noa Sher, Ph.D., added that the designation marks an important milestone in the company’s goal to improve outcomes for patients with mitochondrial-related diseases.

In a related development, Minovia also announced a definitive business combination agreement with special purpose acquisition company Launch One Acquisition Corp. The merger, expected to close in late 2025, will take Minovia public on Nasdaq under a new ticker symbol.

This advancement positions Minovia to accelerate clinical development of MNV-201 and expand its pipeline of innovative mitochondrial therapies.